Pfizer Prospects Garner Mixed Sentiment From Analysts: ‘Finally, The Pivot Investors Have Been Waiting For’
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work.
Why Is Medical Device Maker Baxter Stock Trading Lower On Thursday?
Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a reported basis.
Nasdaq Gains Over 200 Points; Dentsply Sirona Shares Fall After Q1 Results
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging over 200 points on…
Carvana’s Strong Q1 Performance Attracts Analysts Praise, Stock Soars
Carvana shares are jumping today following yesterday's first-quarter FY24 results. Several analysts raised the price target on the stock.
Dominion Energy Reports Mixed Bag Of Q1 Earnings, Sticks To Annual Guidance
Dominion Energy reported Q1 FY24 revenue of $3.632B, missing consensus of $4.380B. Adjusted EPS was $0.55 and company reaffirms FY24 and FY25 guidance.
Organon Beats On Q1, Women’s Health Leads the Charge
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
Why Bausch Health Companies Shares Are Falling After Q1 Results
Bausch Health misses Q1 EPS estimates at 59 cents, despite a revenue increase of 11%.
Wall Street Inches Up Post Fed; Chipmakers Rebound; Gold, Crude Falter: What’s Driving Market Thursday?
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.
Thomson Reuters Triumphs in Q1 Backed by AI Product Roadmap and Strategic Acquisitions
Thomson Reuters Corp reported Q1 2024 revenue growth of 8%, beating analyst consensus, with adjusted EPS of $1.11. The stock gained, driven by 9% organic revenue growth. CEO is confident in their AI product roadmap. Outlook is $7.24-$7.27 billion. Stock up 17% in last 12 months.
Why CNH Industrial Shares Are Gaining today
CNH Industrial reported lower Q1 2024 results, with revenue down 10% Y/Y. Adjusted EPS of $0.33 beat consensus of $0.27. 2024 outlook lowered.